全文获取类型
收费全文 | 1300篇 |
免费 | 39篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 24篇 |
儿科学 | 25篇 |
妇产科学 | 19篇 |
基础医学 | 135篇 |
口腔科学 | 9篇 |
临床医学 | 118篇 |
内科学 | 363篇 |
皮肤病学 | 4篇 |
神经病学 | 111篇 |
特种医学 | 55篇 |
外科学 | 265篇 |
综合类 | 4篇 |
预防医学 | 68篇 |
眼科学 | 7篇 |
药学 | 52篇 |
中国医学 | 8篇 |
肿瘤学 | 78篇 |
出版年
2023年 | 10篇 |
2022年 | 29篇 |
2021年 | 65篇 |
2020年 | 22篇 |
2019年 | 44篇 |
2018年 | 51篇 |
2017年 | 25篇 |
2016年 | 23篇 |
2015年 | 37篇 |
2014年 | 53篇 |
2013年 | 86篇 |
2012年 | 123篇 |
2011年 | 112篇 |
2010年 | 57篇 |
2009年 | 35篇 |
2008年 | 85篇 |
2007年 | 70篇 |
2006年 | 64篇 |
2005年 | 55篇 |
2004年 | 51篇 |
2003年 | 50篇 |
2002年 | 58篇 |
2001年 | 12篇 |
2000年 | 7篇 |
1999年 | 7篇 |
1997年 | 9篇 |
1996年 | 4篇 |
1995年 | 3篇 |
1994年 | 3篇 |
1993年 | 3篇 |
1992年 | 8篇 |
1991年 | 5篇 |
1990年 | 4篇 |
1989年 | 4篇 |
1988年 | 4篇 |
1986年 | 7篇 |
1985年 | 6篇 |
1984年 | 2篇 |
1983年 | 7篇 |
1981年 | 2篇 |
1980年 | 4篇 |
1979年 | 3篇 |
1978年 | 3篇 |
1977年 | 2篇 |
1976年 | 2篇 |
1975年 | 7篇 |
1974年 | 3篇 |
1973年 | 7篇 |
1972年 | 3篇 |
1969年 | 2篇 |
排序方式: 共有1345条查询结果,搜索用时 15 毫秒
71.
Guiard-Schmid JB Poirier JM Meynard JL Bonnard P Gbadoe AH Amiel C Calligaris F Abraham B Pialoux G Girard PM Jaillon P Rozenbaum W 《Antimicrobial agents and chemotherapy》2003,47(3):986-990
Ritonavir (RTV) strongly increases the concentrations of protease inhibitors (PIs) in plasma in patients given a combination of RTV and another PI. This pharmacological interaction is complex and poorly characterized and shows marked inter- and intraindividual variations. In addition, RTV interacts differently with saquinavir (SQV), indinavir (IDV), amprenavir (APV), and lopinavir (LPV). In this retrospective study on 542 human immunodeficiency virus-infected patients, we compared inter- and intraindividual variability of plasma PI concentrations and correlations between the C(min) (minimum concentration of drug in plasma) values for RTV and the coadministered PI C(min) values. Mean RTV C(min)s are significantly lower in patients receiving combinations containing APV or LPV than in combinations with SQV or IDV. With the most common PI dose regimens (600 mg of IDV twice a day [BID], 800 mg of SQV BID, and 400 mg of LPV BID), the interindividual C(min) variability of patients treated with a PI and RTV seemed to be lower with APV and LPV than with IDV and SQV. As regards intraindividual variability, APV also differed from the other PIs, exhibiting lower C(min) variability than with the other combinations. Significant positive correlations between RTV C(min) and boosted PI C(min) were observed with IDV, SQV, and LPV, but not with APV. Individual dose adjustments must take into account the specificity the pharmacological interaction of each RTV/PI combination and the large inter- and intraindividual variability of plasma PI levels to avoid suboptimal plasma drug concentrations which may lead to treatment failure and too high concentrations which may induce toxicity and therefore reduce patient compliance. 相似文献
72.
Martin JB Wetzel SG Seium Y Dietrich PY Somon T Gailloud P Payer M Kelekis A Ruefenacht DA 《Radiology》2003,229(2):593-597
For the treatment of lytic disease involving the pedicles of vertebrae in patients with metastatic disease, the authors performed percutaneous vertebroplasty by using an access route via the lysed pedicle. Fifty-one pedicles were treated in 32 consecutive patients. In all cases, a radiologically satisfactory filling of both the affected pedicle and the vertebral body was achieved. Clinically effective pain relief was obtained in 24 (75%) of 32 patients, and no clinical complications were observed. 相似文献
73.
The antiemetic efficacy of droperidol added to morphine patient-controlled analgesia: a randomized,controlled, multicenter dose-finding study 总被引:3,自引:0,他引:3
The antiemetic dose response of droperidol when it is added to patient-controlled analgesia with morphine is not well known. We randomly allocated adults who received postoperative morphine patient-controlled analgesia (1-mg bolus, 5-min lockout) to one of four regimens: no droperidol (control) or 5, 15, or 50 micro g of droperidol per milligram of morphine. Efficacy and adverse effects were recorded during 24 h and were analyzed with number needed to treat (NNT) and number needed to harm with 95% confidence intervals. Data from 82 controls, 82 patients receiving droperidol 5 micro g, 82 receiving droperidol 15 micro g, and 83 receiving droperidol 50 micro g were analyzed. Average consumption of droperidol per 24 h was 0.2 mg with the 5- micro g regimen, 0.61 mg with the 15- micro g regimen, and 2.04 mg with the 50- micro g regimen. In controls, the incidence of nausea was 48.8%; with droperidol 5 micro g, it was 42.7% (NNT compared with control, 16 [95% confidence interval, 4.7 to -11]); with 15 micro g, it was 32.9% (NNT, 6.3 [3.3-100]); and with 50 micro g, it was 21.7% (NNT, 3.7 [2.4 to 7.6]). In controls, the incidence of vomiting was 24.4%; with droperidol 5 micro g, it was 23.2% (NNT compared with control, 82 [7 to -8.5]); with 15 micro g, it was 22.0% (NNT, 41 [6.5 to -9.6]); and with 50 micro g, it was 12% (NNT, 8.1 [4.2-142]). In controls, the incidence of pruritus was 12.2%; with droperidol 5 micro g, it was 6.1% (NNT compared with control, 16 [6.7 to -37]); and with 15 and 50 micro g, it was 2.4% (NNT, 10 [5.7-52]). In controls, the incidence of sedation was 2.4%; with droperidol 5 micro g, it was 8.5% (number needed to harm (NNH) compared with control, 16 [7.7 to -123]); with 15 micro g, it was 6.1% (NNH, 27 [10 to -40]); and with 50 micro g, it was 18.1% (NNH, 6.4 [4.1-15]). There were no extrapyramidal symptoms and no cardiac adverse events. There was no difference in patient satisfaction. The optimal antiemetic dose of droperidol is 15-50 micro g/mg of morphine. Larger doses may have more antivomiting efficacy but are likely to be unacceptably sedating. 相似文献
74.
75.
Management of primary anal canal adenocarcinoma: a large retrospective study from the Rare Cancer Network 总被引:2,自引:0,他引:2
Belkacémi Y Berger C Poortmans P Piel G Zouhair A Méric JB Nguyen TD Krengli M Behrensmeier F Allal A De Looze D Bernier J Scandolaro L Mirimanoff RO;Rare Cancer Network 《International journal of radiation oncology, biology, physics》2003,56(5):1274-1283
PURPOSE: Primary adenocarcinoma of the anus is a rare tumor. The current standard treatment consists of abdominoperineal resection (APR). The aim of this Rare Cancer Network study was to evaluate the prognostic factors and outcome after the three most commonly used treatment approaches. METHODS AND MATERIALS: This multicenter study collected data from 82 patients: 15 with T1 (18%), 34 with T2 (42%), 22 with T3 (27%), and 11 with T4 (13%) tumors according to the TNM classification (International Union Against Cancer, 1997). Patients were separated into, and analyzed according to, three treatment categories: radiotherapy/surgery (RT/S group, n = 45), combined radiochemotherapy (RT/CHT group, n = 31), and APR alone (APR group, n = 6). The main patient characteristics were evenly distributed among the three groups. RESULTS: The actuarial locoregional relapse rate at 5 years was 37%, 36%, and 20%, respectively, in the RT/S, RT/CHT, and APR groups (RT/S vs. RT/CHT, p = 0.93; RT/CH vs. APR, p = 0.78). The 3-, 5-, and 10-year overall survival rate was 47%, 29%, and 23% in the RT/S group, 75%, 58%, and 39% in the RT/CHT group, and 42%, 21%, and 21% in the APR group (RT/CHT vs. RT/S, p = 0.027), respectively. The 5- and 10-year disease-free survival rate was 25% and 18% in the RT/S group, 54% and 20% in the RT/CHT group, and 22% and 22% in the APR group (RT/CHT vs. RT/S, p = 0.038), respectively. Multivariate analysis revealed four independent prognostic factors for survival: T stage, N stage, histologic grade, and treatment modality. CONCLUSION: Primary adenocarcinoma of the anal canal requires rigorous management. Multivariate analysis showed that T and N stage, histologic grade, and treatment modality are independent prognostic factors for survival. We observed better survival rates after combined RT/CHT. We also recommend using APR only for salvage treatment. 相似文献
76.
Interleukin-9 (IL-9) stimulates the proliferation of mast cells and lymphocytes. In the present study, we showed that IL-9 induced a transient phosphorylation of MEK, ERK2 and p90/RSK in murine lymphoid and mast cell lines. ERK2 in vitro kinase activity was also increased upon IL-9 stimulation. Similar results were obtained with IL-4, which had not been previously reported to activate these kinases in hematopoietic cells. Analysis of IL-9 receptor mutants showed that activation of the pathway was correlated with proliferation and with phosphorylation of the adaptor protein SHC, but not IRS2 or GAB2. The MEK inhibitor PD98059 reduced the mitogenic response to IL-4 and IL-9. In addition, expression of a dominant-negative RAS variant blocked ERK phosphorylation and significantly decreased Ba/F3 cell growth in the presence of IL-9, but did not affect expression of pim-1, a STAT target gene. In summary, these results indicate that IL-9 can transiently activate the mitogen-activated protein kinase pathway, which contributes to growth stimulation of hematopoietic cell lines. 相似文献
77.
Bitonte DA Curry P Butler P Nowak MJ Jean-Baptiste R Feigenbaum RA 《Topics in health information management》2001,21(4):50-62
Peer Review Organizations (PROs) are charged by the Health Care Financing Administration (HCFA) to assist in protecting the integrity and solvency of the Medicare program. Recent audits of the Medicare program from the Office of Inspector General (OIG) revealed that more than $12 billion Medicare dollars in 1998 were spent in improper payments, with more than 25% attributed to prospective payment system (PPS) hospitals. The Payment Error Prevention Program (PEPP) is an initiative designed by HCFA in 1999 to assist PROs in meeting the goal of reducing payment errors in PPS hospitals. PEPP is implemented through the development of quality improvement (QI) methodologies. These projects are designed to achieve measurable improvements in processes and outcomes of payment errors. PEPP works to reduce payment errors at PPS hospitals through cooperative efforts with Ohio agencies and licensing boards, federal law enforcement organizations, HCFA contractors, hospital medical staffs, and medical and osteopathic associations. 相似文献
78.
79.
80.